Record ID	
The Global Health Research Group for Children's N	Ion-Communicable Diseases (Global
Children's NCDs ) wishes to thank you for being a	
multi-center study looking at the impact of the Co	ronavirus disease (COVID-19) on the care of
childhood cancers: COVIDPaedsCancer	
In order to contribute to COVIDPaedsCancer you should first secure local study approval.	○ Yes ○ No
Has local study approval been secured?	
Please secure local study approval before adding any patient	data onto REDCap
Date of birth	
	(Day-Month-Year)
Does this patient have a tumour?	○ Yes ○ No
This patient does not meet the inclusion criteria for COVIDPa	edsCancer
Sex	⊖ Female
	<ul><li>○ Male</li><li>○ Ambiguous</li></ul>
Weight (kg)	
	(First weight undertaken during admission)
ASA Grade	<ul> <li>1 - a normal healthy patient</li> <li>2 - a patient with mild systemic disease</li> <li>3 - a patient with severe systemic disease</li> <li>4 - a patient with severe systemic disease that is a constant threat to life</li> <li>5 - a moribund patient who is not expected to survive without the operation</li> <li>(ASA (American Society of Anesthesiologists) grade at the time of surgery)</li> </ul>

### **Tumour Details**

Diagnostic group/subgroup of tumour	<ul> <li>Acute lymphoblastic leukaemia</li> <li>Hodgkin lymphoma</li> <li>Non-Hodgkin lymphoma</li> <li>Neuroblastoma</li> <li>Wilms Tumour</li> <li>Rhabdomyosarcoma</li> <li>Osteosarcoma</li> <li>Ewings sarcoma</li> <li>Retinoblastoma</li> <li>Glioma</li> <li>Medulloblastoma</li> </ul>
Grade of glioma	<ul> <li>Low grade (WHO grade I/II)</li> <li>High grade (WHO grade III/IV)</li> <li>Unknown</li> </ul>
Staging	<ul> <li>CNS negative (CNS 1)</li> <li>CNS positive (CNS 2/3)</li> <li>Unknown</li> <li>(Central nervous system (CNS) disease: the presence of leukemia cells in the cerebral spinal fluid)</li> </ul>
Staging	<ul> <li>Ann Arbor-stage IA/B</li> <li>Ann Arbor-stage IIA/B</li> <li>Ann Arbor-stage IIIA/B</li> <li>Ann Arbor-stage IVA/B</li> <li>Unknown</li> </ul>
Staging	<ul> <li>Localised</li> <li>Regional</li> <li>Metastatic</li> <li>Unknown</li> </ul>
Date of diagnosis	
	(Day-Month-Year)
What was the initial MDT (tumour board) decision for managing this tumour? (select all that apply)	<ul> <li>Chemotherapy</li> <li>Radiotherapy</li> <li>Immunological therapy</li> <li>Surgery</li> <li>No anticancer therapy</li> </ul>
Date of treatment decision by the tumour board	
	(Day-Month-Year)
Would this decision have been different prior to the COVID-19 pandemic?	○ Yes ○ No
What would the pre-COVID 19 decision for managing this tumour be?	<ul> <li>Chemotherapy</li> <li>Radiotherapy</li> <li>Immunological therapy</li> <li>Surgery</li> <li>No anticancer therapy</li> </ul>

REDCap

# Chemotherapy

Did the patient have chemotherapy during the study window? (12/03/2020 to the 12/06/2020)	○ Yes ○ No
Did the patient have chemotherapy during the 90-day follow up period?	○ Yes ○ No
Is there still a plan for chemotherapy treatment?	○ Yes ○ No
Were there any changes to the chemotherapy treatment due to the COVID-19 pandemic?	<ul> <li>No change to chemotherapy care because of COVID-19</li> <li>Chemotherapy treatment cancelled because of COVID-19</li> </ul>
	<ul> <li>Chemotherapy treatment delayed because of COVID-19</li> <li>Reduction from typical chemotherapy dose because of COVID-19</li> </ul>
	Increase from typical chemotherapy dose because of COVID-19
	Reduction in the number of cycles of chemotherapy because of COVID-19
	Increase in the number of cycles of chemotherapy because of COVID-19
	<ul> <li>Shorter duration of treatment because of COVID-19</li> <li>Longer duration of treatment because of COVID-19</li> <li>Change in choice of chemotherapy agent</li> <li>Change in route of administration of chemotherapy agent</li> </ul>
	Change to/addition of an alternative anti-cancer treatment modality because of COVID-19

REDCap

	What were the reasons for the change(s) to the treatment?	<ul> <li>Change in treatment as per local MDT / hospital policy (decision making)</li> <li>Change in treatment as per regional policy (decision making)</li> <li>Change in treatment as per national policy (decision making)</li> <li>Change in treatment plan by lead clinician (decision making)</li> <li>Lockdown/Travel restrictions prevent access to treatment (infrastructure)</li> <li>Lack of hospital inpatient beds (infrastructure)</li> <li>Lack of hospital intensive care beds (infrastructure)</li> <li>Lack of outpatient facilities for support post-discharge (infrastructure)</li> <li>Lack of personal protective equipment (infrastructure)</li> <li>Lack of drugs (infrastructure)</li> <li>Insufficient staff due to restructuring of services (service delivery)</li> <li>Transfer to a different institution for treatment (service delivery)</li> <li>Inability to pay for treatment (financing)</li> <li>Loss of employment by caregiver (financing)</li> <li>Patient/patient's family chooses to avoid treatment during the pandemic (patient factors)</li> <li>Treatment not possible as caregiver infected with Coronavirus and under mandatory isolation (patient factors)</li> <li>Other</li> </ul>
--	--	---

treatment: other



# Radiotherapy

Did the patient have radiotherapy during the study window? $(12/03/2020 to the 12/06/2020)$	○ Yes ○ No
Did the patient have radiotherapy during the 90-day follow up period?	○ Yes ○ No
Is there still a plan for radiotherapy treatment?	○ Yes ○ No
Were there any changes to the radiotherapy treatment due to the COVID-19 pandemic?	<ul> <li>No change to radiotherapy care because of COVID-19</li> <li>Radiotherapy treatment cancelled because of COVID-19</li> <li>Radiotherapy treatment delayed because of COVID-19</li> <li>Decrease in typical radiotherapy dose per fraction because of COVID-19</li> <li>Increase in typical radiotherapy dose per fraction because of COVID-19</li> <li>Increase in typical radiotherapy dose per fraction because of COVID-19</li> <li>Increase in duration from typical radiotherapy length of treatment because of COVID-19</li> <li>Increase in duration from typical radiotherapy length of treatment because of COVID-19</li> <li>Change in radiotherapy modality because of COVID-19</li> <li>Change to/addition of an alternative anti-cancer treatment modality because of COVID-19</li> </ul>

projectredcap.org

What were the reasons for the change(s) to the treatment?	<ul> <li>☐ Change in treatment as per local MDT / hospital policy (decision making)</li> <li>☐ Change in treatment as per regional policy (decision making)</li> <li>☐ Change in treatment as per national policy (decision making)</li> <li>☐ Change in treatment plan by lead clinician (decision making)</li> <li>☐ Lockdown/Travel restrictions prevent access to treatment (infrastructure)</li> <li>☐ Lack of hospital inpatient beds (infrastructure)</li> <li>☐ Lack of hospital intensive care beds (infrastructure)</li> <li>☐ Lack of outpatient facilities for support post-discharge (infrastructure)</li> <li>☐ Lack of personal protective equipment (infrastructure)</li> <li>☐ Lack of equipment (infrastructure)</li> <li>☐ Lack of drugs (infrastructure)</li>     &lt;</ul>
What were the reasons for the change(s) to the treatment: other	
What was the radiation field?	<ul> <li>Craniospinal</li> <li>Focal (brain)</li> </ul>
What was the radiation field?	<ul><li>◯ Local</li><li>◯ Wide field</li></ul>
Radiotherapy approach	<ul> <li>Photon</li> <li>Proton beam</li> </ul>
Did this represent a change to your typical radiotherapy approach in the pre-COVID-19 era?	<ul> <li>No change to radiotherapy approach</li> <li>Yes, chose to avoid photon radiotherapy related to COVID-19</li> <li>Yes, chose to avoid proton heam radiotherapy</li> </ul>

 $\bigcirc$  Yes, chose to avoid proton beam radiotherapy related to COVID-19



# **Immunological Therapy**

Did the patient have immunotherapy during the study window? (12/03/2020 to the 12/06/2020)	○ Yes ○ No
Did the patient have immunotherapy during the 90-day follow up period?	○ Yes ○ No
Is there still a plan for immunotherapy treatment?	○ Yes ○ No
Were there any changes to the immunotherapy treatment due to the COVID-19 pandemic?	<ul> <li>No change to immunotherapy care because of COVID-19</li> <li>Immunotherapy treatment cancelled because of COVID-19</li> <li>Immunotherapy treatment delayed because of COVID-19</li> <li>Change in typical immunotherapy dose because of COVID-19</li> <li>Change in typical immunotherapy length of treatment because of COVID-19</li> <li>Change to/addition of an alternative anti-cancer treatment modality because of COVID-19</li> </ul>



What were the reasons for the change(s) to the treatment?	Change in treatment as per local MDT / hospital policy (decision making)
	Change in treatment as per regional policy (decision making)
	Change in treatment as per national policy (decision making)
	Change in treatment plan by lead clinician (decision making)
	Lockdown/Travel restrictions prevent access to treatment (infrastructure)
	<ul> <li>Lack of hospital inpatient beds (infrastructure)</li> <li>Lack of hospital intensive care beds (infrastructure)</li> </ul>
	Lack of outpatient facilities for support post-discharge (infrastructure)
	<ul> <li>Lack of blood products (infrastructure)</li> <li>Lack of personal protective equipment (infrastructure)</li> </ul>
	<ul> <li>Lack of equipment (infrastructure)</li> <li>Lack of drugs (infrastructure)</li> </ul>
	Insufficient staff due to redeploymnent/restructuring (workforce)
	<ul> <li>Insufficient staff due to sickness (workforce)</li> <li>No treatment available due to restructuring of</li> </ul>
	services (service delivery)
	(service delivery)
	Inability to pay for treatment (financing) Loss of employment by caregiver (financing)
	Patient/patient's family chooses to avoid
	treatment during the pandemic (patient factors) <ul> <li>Treatment not possible as caregiver infected with</li> <li>Coronavirus and under mandatory isolation (patien</li> </ul>
	factors)
What were the reasons for the change(s) to the	
treatment: other	



Surgery

Did the patient have surgery during the study window? (12/03/2020 to the 12/06/2020)	⊖ Yes ⊖ No
Did the patient have surgery during the 90-day follow up period?	○ Yes ○ No
Date of surgery	
	(Day-Month-Year)
Is there still a plan for surgical treatment?	○ Yes ○ No
Were there any changes to the surgical treatment due to the COVID-19 pandemic?	<ul> <li>No change to operative care because of COVID-19</li> <li>Operation not offered because of COVID-19</li> <li>Operation abandoned because of COVID-19</li> <li>Operation delayed because of COVID-19</li> <li>Change in choice of operation</li> <li>Operation performed in an alternative hospital         <ul> <li>(e.g. designated COVID-free)</li> <li>Interventional radiology procedure performed             before surgery where this would not typically have             been indicated</li> <li>Underwent neoadjuvant therapy where this would not             typically have been indicated</li> <li>Underwent a longer or more intensive course of             neoadjuvant therapy that would have typically been             indicated</li>             Underwent a shorter or less intensive course of             neoadjuvant therapy that would have typically been             indicated</ul></li>             Underwent adjuvant therapy where this would not             typically have been indicated             Underwent a course of neoadjuvant therapy that would have typically been             indicated             Underwent a djuvant therapy where this would not             typically have been indicated             No adjuvant therapy, where this would typically             have been indicated             No adjuvant therapy where this would typically             have been indicated             No adjuvant therapy where this would typically             have been indicated             Not recruited to a clinical trial, where this             would typically have been offered             Recruited to a clinical trial, where this would             not have previously been offered             Changed to active palliative care instead of             operative care </ul>



What were the reasons for the change(s) to the treatment?	<ul> <li>Change in treatment as per local MDT / hospital policy (decision making)</li> <li>Change in treatment as per regional policy (decision making)</li> <li>Change in treatment as per national policy (decision making)</li> <li>Change in treatment plan by lead clinician (decision making)</li> <li>Lockdown/Travel restrictions prevent access to treatment (infrastructure)</li> <li>Lack of hospital inpatient beds (infrastructure)</li> <li>Lack of hospital intensive care beds (infrastructure)</li> <li>Lack of outpatient facilities for support post-discharge (infrastructure)</li> <li>Lack of personal protective equipment (infrastructure)</li> <li>Lack of drugs (infrastructure)</li> <li>Insufficient staff due to redeploymnent/restructure)</li> <li>Insufficient staff due to restructuring of services (service delivery)</li> <li>Transfer to a different institution for treatment (service delivery)</li> <li>Inability to pay for treatment (financing)</li> <li>Loss of employment by caregiver (financing)</li> <li>Patient/patient's family chooses to avoid treatment during the pandemic (patient factors)</li> <li>Treatment not possible as caregiver infected with Coronavirus and under mandatory isolation (patient factors)</li> </ul>
What were the reasons for the change(s) to the	☐ Other
treatment: other	
What type of hospital was the operation performed in?	<ul> <li>Designated COVID-free 'cold' hospital</li> <li>Designated COVID-treatment 'hot' hospital</li> <li>Undesignated hospital type with emergency department</li> <li>Undesignated hospital type without emergency department</li> </ul>
Time from admission to operation (preoperative delay)	<pre>     &lt; 6 hours     </pre> <pre>         6-23 hours         24-47 hours         48-71 hours         72+ hours         </pre>



Urgency of surgery	<ul> <li>IMMEDIATE - life, limb or organ-saving intervention - within minutes of decision to operate</li> <li>URGENT - within hours of decision to operate</li> <li>EXPEDITED - patient requiring early treatment but no immediate threat to life, limb or organ - within days of decision to operate</li> <li>ELECTIVE - Intervention planned or booked in advance of routine admission to hospital</li> <li>(Full definitions available at: https://www.ncepod.org.uk/classification.html)</li> </ul>
What was the reason urgent or emergency cancer surgery was required?	<ul> <li>Gastro-intestinal obstruction</li> <li>Bleeding</li> <li>Sepsis</li> <li>Tumour progression</li> <li>Organ perforation</li> <li>Functional compromise</li> <li>Other</li> </ul>
Other reason for why urgent or emergency cancer surgery was required	
Did the patient have a mandatory self-isolation period before elective surgery?	<ul> <li>Yes, two weeks or more</li> <li>Yes, less than two weeks</li> <li>No</li> </ul>
Was screening for COVID-19 performed within the 72 hours before surgery?	<ul> <li>No</li> <li>Yes - Laboratory test</li> <li>Yes - CT thorax</li> <li>Yes - Symptomatic screening or questionnaire only</li> <li>Yes - Other</li> </ul>
Screening: Other	
Was the patient known to have COVID-19 infection before the time of surgery?	<ul> <li>Yes - proven with laboratory test or CT Thorax</li> <li>Probable - clinically suspected</li> <li>No</li> <li>Unknown</li> </ul>
Had the COVID-19 infection resolved?	○ Yes ○ No
How long before the date of surgery was COVID-19 diagnosed?	<ul> <li>Less than 1 week</li> <li>2 to 4 weeks</li> <li>5 to 8 weeks</li> <li>Greater than 8 weeks</li> </ul>
What was the primary purpose of the surgery?	<ul> <li>Diagnostic</li> <li>Curative</li> <li>Palliative</li> </ul>
Type of anaesthesia used?	<ul> <li>◯ Local</li> <li>◯ Regional</li> <li>◯ General</li> </ul>



Operative approach	<ul> <li>Open</li> <li>Minimally-invasive</li> <li>Minimally-invasive converted to open</li> </ul>
Did this represent a change to your typical operative approach in the pre-COVID-19 era?	<ul> <li>No change to operative approach</li> <li>Yes, chose to avoid minimally invasive surgery related to COVID-19</li> <li>Yes, chose to avoid open surgery related to COVID-19</li> </ul>
Designation of the operating theatre	<ul> <li>Designated COVID treatment area (only COVID patients treated there)</li> <li>Designated non-COVID treatment area (only non-COVID patients treated there)</li> <li>No designation for this area (either COVID or non-COVID patients can be treated there)</li> <li>Not applicable</li> </ul>
Designation of the intensive care unit	<ul> <li>Designated COVID treatment area (only COVID patients treated there)</li> <li>Designated non-COVID treatment area (only non-COVID patients treated there)</li> <li>No designation for this area (either COVID or non-COVID patients can be treated there)</li> <li>Not applicable</li> </ul>
Would a post-operative intensive care unit stay have been planned in a pre-COVID-19 era?	○ Yes ○ No
Designation of the postoperative ward	<ul> <li>Designated COVID treatment area (only COVID patients treated there)</li> <li>Designated non-COVID treatment area (only non-COVID patients treated there)</li> <li>No designation for this area (either COVID or non-COVID patients can be treated there)</li> <li>Not applicable</li> </ul>
Was a post-operative CT head performed?	○ Yes ○ No
Did any of the operating surgeons contract COVID-19 within 30-days of the date of surgery?	○ Yes ○ No



### **No Anticancer Treatment**

Did the patient or their family choose to avoid treatment during the pandemic before the initial MDT (tumour board) meeting?	○ Yes ○ No
Was the patient given palliative treatment?	○ Yes ○ No
Were there any changes to the palliative care treatment due to the COVID-19 pandemic?	<ul> <li>No change to palliative care because of COVID-19</li> <li>Palliative treatment *not* provided because of COVID-19</li> <li>Palliative treatment provided because of COVID-19</li> <li>Palliative treatment delayed because of COVID-19</li> <li>Change from typical palliative care plan because of COVID-19</li> </ul>
What were the reasons for the change to palliative care treatment?	<ul> <li>☐ Change in treatment as per local MDT / hospital policy (decision making)</li> <li>☐ Change in treatment as per regional policy (decision making)</li> <li>☐ Change in treatment as per national policy (decision making)</li> <li>☐ Change in treatment plan by lead clinician (decision making)</li> <li>☐ Change in treatment plan by lead clinician (decision making)</li> <li>☐ Lockdown/Travel restrictions prevent access to treatment (infrastructure)</li> <li>☐ Lack of hospital inpatient beds (infrastructure)</li> <li>☐ Lack of outpatient facilities for support post-discharge (infrastructure)</li> <li>☐ Lack of personal protective equipment (infrastructure)</li> <li>☐ Lack of drugs (infrastructure)</li> <li>☐ Insufficient staff due to redeploymnent/restructuring (workforce)</li> <li>☐ Insufficient staff due to sickness (workforce)</li> <li>☐ No treatment available due to restructuring of services (service delivery)</li> <li>☐ Transfer to a different institution for treatment (service delivery)</li> <li>☐ Inability to pay for treatment (financing)</li> <li>☐ Loss of employment by caregiver (financing)</li> <li>☐ Patient/patient's family chooses to avoid treatment during the pandemic (patient factors)</li> <li>☐ Treatment not possible as caregiver infected with Coronavirus and under mandatory isolation (patient factors)</li> <li>☐ Other</li> </ul>
What were the reasons for the change to palliative	

What were the reasons for the change to palliative care treatment: other



**Outcomes** 

Was screening for COVID-19 performed within 30 days post-surgery?	<ul> <li>No</li> <li>Yes - Laboratory test</li> <li>Yes - CT thorax</li> <li>Yes - Symptomatic screening or questionnaire only</li> <li>Yes - Other</li> </ul>
Was screening for COVID-19 performed within 30 days post-surgery: other	
Was the patient diagnosed with COVID-19 within 30 days from their first anti-cancer treatment post March 11th 2020?	<ul> <li>Yes - proven with laboratory test or CT Thorax</li> <li>Probable - clinically suspected</li> <li>No</li> <li>Unknown</li> </ul>
Complications within 30 days post-surgery?	<ul> <li>Anaesthetic complications</li> <li>Anastomotic leak</li> <li>Blood transfusion</li> <li>Cardiac arrest</li> <li>Pneumonia</li> <li>Sepsis</li> <li>Wound dehiscence</li> <li>Line Infection</li> <li>Neurological injury</li> <li>Vascular injury</li> <li>Altered bowel and bladder function</li> <li>Other loss of function</li> <li>Early recurrence / Incomplete clearance</li> </ul>
Outcomes at 30 days from their first anti-cancer treatment post March 11th 2020?	<ul> <li>Died - during surgery</li> <li>Died - on days 0-7 after surgery</li> <li>Died - on days 8-30 after surgery</li> <li>Alive - remains admitted in hospital</li> <li>Alive - transferred to another hospital</li> <li>Alive - discharged to a rehabilitation centre</li> <li>Alive - discharged home</li> </ul>
Mortality at 90 days from their first anti-cancer treatment post March 11th 2020?	<ul> <li>○ Alive</li> <li>○ Dead</li> <li>○ Unknown</li> </ul>
Total length of hospital stay (days)	
Mortality at 1 year from their first anti-cancer treatment post March 11th 2020?	<ul> <li>Alive</li> <li>Dead</li> <li>Unknown</li> </ul>

